

Page 1 of 2

## URGENT: DRUG RECALL SECOND NOTICE INTERNAL RECALL #: 456

April 30, 2025

51991-00456-01214506 INDEPENDENT PHARM DIST 1107 W MARKET CENTER DRIVE HIGH POINT, NC 27260

To Whom It May Concern:

Please be advised that *Breckenridge Pharmaceutical, Inc.* (Breckenridge) is voluntarily performing a Retail Level Recall of **Duloxetine Delayed-Release Capsules, USP, 30mg**, manufactured by Towa Pharmaceutical Europe, S.L. Refer to accompanying image of the capsules. This Retail Level Recall affects the lot in the table below.

Note: This is the second recall notice. The initial notification was dated March 26, 2025.

Only the lot listed in the table below is being recalled due to presence of Nitrosamine Drug Substance Related Impurity (NDSRI), N-nitroso-duloxetine, above the proposed interim limit.

Product	Size	NDC Number	Affected Lot #	Exp Date
Duloxetine Delayed-Release Capsules USP, 30 mg	1000-count	51991-747-10	240909C	03/2027

These impurities may increase the risk of cancer if people are exposed to them above acceptable levels over long periods of time. To date, Breckenridge is not aware of reports of adverse events that have been assessed to be related to this recall.

This recall is being initiated with the knowledge of the Food and Drug Administration and should be carried out to the Retail Level.

Please examine your stock, determine if you have any of the affected product lot numbers on hand and place affected product into quarantine. If you have any of the affected lots, please complete the "Recall Response Form" and return to Breckenridge's designated recall service provider — Qualanex LLC. Once Qualanex receives your completed response form, they will send you a Return Authorization which should be included with your recall return. You will also receive a Return Label (if you have not already received one) which you can use to return your recalled product.

Return Authorization requests can be made by email at <u>recall@qualanex.com</u>, via telephone at 1-800-505-9291, or by Fax at 1-847-737-3719.

#### Please take the following actions:

- 1) Check your inventory to see if you have any of the recalled product in stock, from the lot listed in the table above. If so, place the product under quarantine, and do not distribute.
- 2) Complete the enclosed 'Recall Response Form" and return via facsimile to Qualanex, LLC at 1-847-737-3719 or via email at recall@qualanex.com.
- 3) If the product was further distributed, please notify sub-accounts to the retail level.

Please contact Qualanex at 1-800-505-9291, Monday – Friday from 9AM – 5PM (EST), should you have any questions or concerns regarding this recall.

Sincerely,

Jacqui Hibbert

Vice President, Quality Assurance



Page 2 of 2

# URGENT: DRUG RECALL SECOND NOTICE INTERNAL RECALL #: 456

Duloxetine Delayed-Release Capsules USP, 30 mg





## BUSINESS RESPONSE FORM URGENT: DRUG RECALL—SECOND NOTICE

#### Internal Recall # 456

Product Name	Pack Size	NDC Number	Lots involved
	1000-count	51991-747-10	240909C
Dułoxetine Delayed-Release Capsules USP, 30mg			

This recall is being carried out at retail level.

<u>Please fill out this form completely</u>. By doing so, this will acknowledge that you have read and understand the recall instructions and have taken the appropriate action.

Customer Facility Name	
Address	
City, State, Zip	
Contact name	
Contact, Phone, Fax, Email	
Wholesaler Name and Address	
[ ] I have read and understand 2025	d the recall instructions provided on the recall notification letter dated April 30,
[ ] I have checked my stock fo	or the recalled lots listed in the above table:
[ ] Do not have any stock of t	he recalled items.
OR	
[ ] I have quarantined and list QUALANEX as soon as possible	red in the table below the quantity of recall units I will be returning to e.
Upon receipt of this Response the product.	Form, QUALANEX will issue a Return Authorization to be included with

NDC	Lot#	Qty. Sealed bottles	Qty. Partial bottles	Notes	
51991-747-10	240909C				



### BUSINESS RESPONSE FORM URGENT: DRUG RECALL-- SECOND NOTICE

### Internal Recall # 456

Adverse reactions or quality problems experienced with the use of this product may be reported to the FDA's MedWatch Adverse Event Reporting program either online by completing and submitting the form at <a href="https://www.accessdata.fda.gov/scripts/medwatch/index.cfm">https://www.accessdata.fda.gov/scripts/medwatch/index.cfm</a>.

FOR WHOLESALERS ONLY:	
# of Retail Pharmacies to be notified:	
Please return a copy of this completed response for email at <a href="mailto:recall@qualanex.com">recall@qualanex.com</a> .	orm via facsimile to Qualanex, LLC at 1-847-737-3719 or via
Completed by:	Date: